IX Biopharma Company Announcements (42C)

SGX Google Yahoo News TradingView

IX BIOPHARMA LTD. (42C) SGD 0.02 +0.00% +0.00

Portfolio Watchlist

All Financial Buy Back Insider Trading

2025-02-22

Extraordinary/ Special General Meeting::Voluntary

2025-02-21

Equity Listing - Ordinary Shares::Issue and Allotment of New Shares Pursuant to iX Performance Share Plan

2025-02-14

Employee Stock Option/ Share Scheme::Grant of Share Awards Pursuant to iX Performance Share Plan

2025-02-07

Financial Statements and Related Announcement::Half Yearly Results

2024-11-15

General Announcement::Minutes of Annual General Meeting Held on 17 October 2024

2024-10-17

REPL::Extraordinary/ Special General Meeting::Voluntary

2024-10-17

REPL::Annual General Meeting::Voluntary

2024-09-30

Annual General Meeting::Voluntary

2024-09-30

Change - Announcement of Cessation::Retirement of Independent Director

2024-09-30

Extraordinary/ Special General Meeting::Voluntary

2024-09-30

Financial Statements and Related Announcement::Auditor's Comments of Accounts

2024-08-12

General Announcement::Press Release - New Study Highlights CBD Wafer's Potential in Kidney Failure Patients

2024-07-24

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung

2024-07-22

REPL::Rights::Voluntary

2024-07-19

General Announcement::Issue and Listing of the Rights Shares and the Warrants

2024-07-15

General Announcement::Notice From Undertaking Shareholder Anson Properties Pte. Ltd.

2024-07-09

General Announcement::Press Release - Breakthrough Sublingual Wafers Raise NAD+ Levels, Enhance Well-Being in Human Trial

2024-07-02

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang

2024-07-02

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung

2024-07-01

General Announcement::Proposed Renounceable Non-Underwritten Rights Cum Warrants Issue: Despatch of Notification and Forms

2024-06-26

REPL::Rights::Voluntary

2024-06-18

General Announcement::Notice of Adjustment to Conversion Price of 9% Convertible Bonds Principal Amount S$2 Million

2024-06-18

REPL::Rights::Voluntary

2024-06-11

REPL::Rights::Voluntary

2024-06-06

Rights::Voluntary

2024-03-20

General Announcement::Update For Shareholders

2024-03-11

General Announcement::Press Release - iX Biopharma Announces Development of Semaglutide Sublingual Wafer, iXB 401

2024-03-04

General Announcement::Press Release - iX Biopharma Unveils Novel NAD Wafers

2024-03-01

General Announcement::Termination Of Wafermine Licensing Agreement

2024-02-05

Financial Statements and Related Announcement::Half Yearly Results

2023-12-01

Employee Stock Option/ Share Scheme::Grant of Share Awards Pursuant to iX Performance Share Plan

2023-11-17

General Announcement::Notice Of Termination Of Wafermine Licensing Agreement

2023-11-10

General Announcement::Minutes of Annual General Meeting Held on 13 October 2023

2023-10-13

REPL::Annual General Meeting::Voluntary

2023-10-11

General Announcement::Responses to Questions from the Securities Investors Association (Singapore)

2023-10-06

General Announcement::Questions & Answers Provided by iX Biopharma Ltd for Annual General Meeting on 13 October 2023

2023-10-04

General Announcement::Corrigenda - Corporate Governance Reports 2022 and 2023

2023-09-29

General Announcement::Press Release - iX Biopharma Introduces MeltMed in USA

2023-09-25

Annual General Meeting::Voluntary

2023-09-25

Annual Reports and Related Documents::

2023-08-21

Financial Statements and Related Announcement::Full Yearly Results

2023-07-24

General Announcement::Proposed Issuance of Convertible Bonds of An Aggregate Principal Amount of S$2,000,000 - Completion

2023-07-17

General Announcement::Proposed Issuance of Convertible Bonds of S$2,000,000 - Receipt of Listing and Quotation Notice

2023-07-03

General Announcement::Proposed Issuance of Convertible Bonds of an Aggregate Principal Amount of S$2,000,000

2023-02-10

Financial Statements and Related Announcement::Half Yearly Results

2023-02-09

General Announcement::Press Release: iX Biopharma Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study

2022-12-02

General Announcement::Reconstitution of the Board Committees

2022-11-11

General Announcement::Minutes of Annual General Meeting Held on 14 October 2022

2022-11-07

Change - Announcement of Appointment::Appointment of Independent Non-Executive Director

2022-11-07

General Announcement::Appointment of Independent Non-Executive Director and Re-Constitution of the Board

© 2025 Dividends.sg / More Countries

© Owned by Little White Pte. Ltd.